Nivolumab‐related tracheobronchial chondritis: Extremely rare manifestation of an immune‐related adverse effect

Head & Neck ◽  
2020 ◽  
Vol 42 (11) ◽  
Author(s):  
Kiyomi Kuba ◽  
Mitsuhiko Nakahira ◽  
Hitoshi Inoue ◽  
Yasunao Kogashiwa ◽  
Yasuhiro Ebihara ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Related Adverse Effect ◽  
Rare Manifestation

A possible prolactin-related adverse effect of certain antineoplastic anthracyclines

2000 ◽  
Vol 116 (3) ◽  
pp. 231-236 ◽  
Author(s):  
Luigi Brunetti ◽  
Giustino Orlando ◽  
Barbara Michelotto ◽  
Lucia Recinella ◽  
Enzo Ragazzoni ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Related Adverse Effect

A case of immune-related adverse effect diffuse gastritis induced by nivolumab

2021 ◽  
Vol 98 (1) ◽  
pp. 91-92
Author(s):  
Miho Sakai ◽  
Yuki Haga ◽  
Michiyo Kambe ◽  
Koji Nishimura ◽  
Ayako Shingyouchi ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Related Adverse Effect

Xerostomia: an immunotherapy-related adverse effect in cancer patients

2021 ◽  
Author(s):  
Hannah Bustillos ◽  
Amy Indorf ◽  
Laura Alwan ◽  
John Thompson ◽  
Lindsey Jung
Keyword(s):  
Adverse Effect ◽  
Cancer Patients ◽  
Related Adverse Effect

PERSISTENT HIGH C2 LEVEL AS A RISK FACTOR FOR DEVELOPING CSA RELATED ADVERSE EFFECT IN STABLE LIVER TRANSPLANT PATIENTS

2004 ◽  
Vol 78 ◽  
pp. 375
Author(s):  
J Li ◽  
U Dahmen ◽  
S Beckebaum ◽  
V Cicinnati ◽  
C Valentin-Gamazo ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Risk Factor ◽  
Liver Transplant ◽  
Transplant Patients ◽  
Related Adverse Effect

Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors

2017 ◽  
Vol 25 (3) ◽  
pp. 544-550 ◽  
Author(s):  
Kiersten J Williams ◽  
Dennis W Grauer ◽  
David W Henry ◽  
Michelle L Rockey
Keyword(s):  
Adverse Effect ◽  
Adverse Effects ◽  
Checkpoint Inhibitor ◽  
Checkpoint Inhibitors ◽  
Cell Activity ◽  
Total Duration ◽  
Inhibitor Therapy ◽  
Related Adverse Effect ◽  
Starting Dose ◽  
Checkpoint Inhibitor Therapy

Introduction Due to enhanced T-cell activity, immune checkpoint inhibitors cause immune-related adverse effects. Corticosteroids are the mainstay of immune-related adverse effect management but the optimal strategy has not been determined, putting patients at risk for steroid-related adverse effects and potentially decreased efficacy of immunotherapy. This study aims to characterize the use of corticosteroids for the management of immune-related adverse effect. Methods and materials A retrospective, single-center evaluation of patients receiving checkpoint inhibitors was conducted. The primary objective was to evaluate corticosteroid use for immune-related adverse effects, including starting dose, taper strategy, total duration, and resumption of immunotherapy. Secondary objective was to describe the incidence and significance of hyperglycemia. Results One hundred and three patients met inclusion criteria and experienced 123 immune-related adverse effects. Prednisone was used most commonly (67%) at an average starting dose of 0.88 mg/kg (range 0.07–17.0). On average, steroid tapers began 9.2 days after initiation (range 0–89) and were continued for a total of 84.2 days (range 3–693). In 21.1% of cases, checkpoint inhibitor therapy was not delayed and 68.6% resumed checkpoint inhibitors, while the patient was taking steroids (30.4 mg prednisone on average, range 5–80). On average, checkpoint inhibitor therapy was resumed 18.6 days after detection of immune-related adverse effect (range 0–150). Clinically relevant hyperglycemia occurred in 8.9%. Conclusion Utilization of steroids for immune-related adverse effect at our institution is highly variable. The majority of patients received prolonged courses of steroids and resumed checkpoint inhibitor therapy with concomitant steroids above recommended doses. Additional monitoring for hyperglycemia and other steroid associated adverse effects should be considered.

scholarly journals VANCOMYCIN ASSOCIATED EOSINOPHILIA & RED MAN SYNDROMEIN A TERTIARY CARE HOSPITAL

2016 ◽  
Vol 8 ◽  
pp. 7
Author(s):  
Adeel Siddiqui ◽  
Keyword(s):  
Adverse Effect ◽  
T Cells ◽  
Hypersensitivity Reaction ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Care Hospital ◽  
Activated T Cells ◽  
Related Adverse Effect ◽  
Red Man Syndrome

Vancomycin associated Red Man Syndrome (RMS) is a common infusion related adverse effect. A correlation has been proposed between vancomycin induced eosinophilia and occurrence of RMS.In such cases, it is identified that activated T-cells release cytokines, which tends to contribute to hypersensitivity reaction.

scholarly journals Impact of Outpatient Chemotherapy-related Adverse Effect on Daily Life and Work Productivity in Breast Cancer Patients

2015 ◽  
Vol 41 (7) ◽  
pp. 515-526 ◽  
Author(s):  
Kazuhide Tanaka ◽  
Tomoya Tachi ◽  
Shoko Asano ◽  
Tomohiro Osawa ◽  
Azusa Kawashima ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adverse Effect ◽  
Cancer Patients ◽  
Daily Life ◽  
Work Productivity ◽  
Breast Cancer Patients ◽  
Outpatient Chemotherapy ◽  
Related Adverse Effect

155 A META-ANALYSIS OF EFFICACY AND SAFETY OF ANTI-BODIES TARGETING PD-1 IN TREATMENT OF ADVANCED ESOPHAGEAL CANCER

2021 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Feng Wang ◽  
Yao Lu ◽  
Xiangrui Meng ◽  
Qingxia Fan
Keyword(s):  
Adverse Effect ◽  
Esophageal Cancer ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
Advanced Esophageal Cancer ◽  
Related Adverse Effect ◽  
Number Of Patients ◽  
First Choice ◽  
Grade 3

Abstract   Systemic chemotherapy is the first choice for patients with advanced esophageal cancer. However, due to drug resistance and dose-limiting toxicity, a large number of patients in China have not been treated. A novel therapy based on programed death 1 (PD-1) inhibitors has been proved to be effective in advanced esophageal cancer.This article is a meta-analysis aiming to systematically evaluate the efficacy and safety of anti-PD-1 therapy in patients with esophageal cancer. Methods Data were collected from eligible studies searched from PubMed, Web of Science, Cochrane Library and Embase. Pooled hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) was estimated to assess the efficacy of PD-1 inhibitors versus chemotherapy, and pooled odds ratio (OR) was calculated for objective response rate (ORR). The analysis among patients tested with different PD-1 status was also performed to figure out the relationship between PD-1 status and efficacy of anti-PD-1 therapy. The OR for occurrence of treatment-related adverse effect was calculated to assess the safety of anti-PD-1 therapy. Results A total of 8 studies were analyzed. Compared with patients with chemotherapy, patients with anti-PD-1 therapy had a significant improvement in OS (HR = 0.80, 95% CI: 0.70–0.91, P = 0.001), but no significant relationship was observed in ORR (HR = 1.87, 95% CI: 0.82–4.25, P = 0.13) and PFS (HR = 0.94, 95% CI: 0.70–1.26, P = 0.67). A similar result was observed in esophageal squamous cell carcinoma (ESCC). The PD-L1 status has no obvious connection with the efficacy of anti-PD-1 therapy. The incidence of grade 3 to 5 treatment-related adverse effect(AE) in anti-PD-1therapy was distinctly lower than that in chemotherapy, but there is no statistical difference in all treatment-related AE. Conclusion Anti-PD-1 therapy significantly prolonged the OS when compared with chemotherapy, while no significantly difference in PFS and ORR for the population of esophageal cancer, ESCC， PD-L1 positive. Based on the analysis of grade 3 to 5 treatment-related adverse effect events, a lower risk was associated with the anti-PD-1 therapy versus chemotherapy.

scholarly journals Associations of Cutaneous Immune-Related Adverse Effects of Immunotherapy With Treatment Response in Patients With Metastatic Melanoma

2021 ◽  
Vol 5 (2) ◽  
pp. 108-117
Author(s):  
Anagha Bangalore Kumar ◽  
Alan Bryce ◽  
Prakash Vishnu ◽  
Svetomir Markovic ◽  
Marian McEvoy
Keyword(s):  
Adverse Effect ◽  
Adverse Effects ◽  
Clinical Response ◽  
Metastatic Melanoma ◽  
Checkpoint Inhibitors ◽  
Logistic Regression Models ◽  
Related Adverse Effect ◽  
Dermatologic Toxicity ◽  
Objective Clinical Response ◽  
Melanoma Patients

Background: Dermatologic toxicity is the most common immune-related adverse effect of cancer immunotherapy. Methods: We retrospectively reviewed the health records of adult (≥18 years) melanoma patients who received ipilimumab, nivolumab, or pembrolizumab from January 1, 2011, through September 15, 2017, at Mayo Clinic. The χ2 test was used to assess the association between development of a cutaneous immune-related adverse effect and antitumoral response to the immune checkpoint inhibitors. Odds ratios were calculated with logistic regression models and were adjusted for sex and immunotherapeutic drugs. We described the various cutaneous immune-related adverse effects and assessed the response to immunotherapy (each patient’s objective clinical response was categorized as favorable [complete or partial response] or unfavorable). We then determined whether development of a cutaneous immune-related adverse effect was associated with the clinical response. Results: Of 690 melanoma patients, 232 (33.6%) had a cutaneous immune-related adverse effect. The most common effects were dermatitis (21.4%), pruritus (5.5%), and vitiligo (4.2%). Median (range) time to onset of dermatitis was 3 (0-7) weeks; lichenoid dermatitis, 12 (6-18) weeks; and vitiligo, 40 (12-96) weeks. Development of a cutaneous immune-related adverse effect was significantly associated with favorable clinical response. Conclusions: Development of cutaneous immune-related adverse effects is associated with favorable responses to nivolumab, ipilimumab, pembrolizumab, and ipilimumab plus nivolumab therapy in patients with metastatic melanoma.

Sign in / Sign up

Export Citation Format

Share Document